and had undergone thyroidectomy for thyroiditis many years before. No thrombophilia was identified.She was treated with warfarin for six months,but soon after eight months direct oral anticoagulants have been resumed for decrease limb thrombophlebitis.The second patient had an axillaryABSTRACT943 of|left vein thrombophlebitis;she reported recurrent unexplained abortions and a benign breast fibroadenoma.The analysis of thrombophilia showed heterozygosis for Element V Leiden.She was treated 1st with enoxaparin for any month,then with sulodexide twice each day for 2 weeks till the symptomatology remitted; now she is on sulodexide daily to prevent thrombosis recurrence.have to have anticoagulant therapy for at the least three months but often “unprovoked” events have a tendency to remain treated life-long, with a relevant bleeding danger. Aims: To assess i) the risk of recurrence inside the long term period (beyond five years), and ii) the influence of other things (presence/discontinuation of therapy, sex, age). Solutions: In this retrospective study we collected data from outpatients throughout follow-up visits at our centre. We compared the risk of recurrence immediately after no less than five years in the diagnosis of VTE between provoked vs unprovoked events and also the Odds Ratio had been calculated. Results: Among 1124 events, 440 (39.1 ) had been unprovoked and 684 (60.9 ) have been provoked. Recurrence occurred in 57 ( ) patients with an unprovoked event and in 78 ( ) patients using a provoked event with worldwide price of recurrence in our population of 12.0 (Odds Ratio (OR) 1.16 (95 self-confidence interval 0.eight.66; P = 0.43). We observed no substantial difference in patients with or with no extended therapy neither in the general population (OR 2.19, 95 self-confidence interval 0.99.83; P = 0.052) nor within the group with an unprovoked occasion (OR 1.17, 95 self-confidence interval 0.47.91; P = 0.73). Conclusions: In our study we located no statistical significance amongst the danger of long-term recurrence, independently in the etiology from the very first occasion or the presence of a “long-term” therapy.PO187|Uncommon Complications of DOAC Remedy FIGURE 2 Left axillary vein reconstruction in breast Magnetic Resonance Imaging with contrast evidences the stop sign resulting from thrombosis (second patient) Conclusions: Our knowledge, though restricted to only two situations,seems to confirm the well-known variability in the causes connected with the onset of MD, too as symptoms and treatment options. Despite the fact that we found a thrombophilic condition in only 1 patient, in our opinion, the presence of ERK1 Activator Storage & Stability congenital or acquired prothrombotic D2 Receptor Inhibitor manufacturer defects should be usually investigated in MD patients to get a greater selection and duration on the anticoagulant remedy. In any case, periodic follow-up checks with Haemostasis and Breast Specialists are needed for a protected and successful MD management. M. Hulikova1; S. Hulik two; J. HulikovaCenter of Hemostasis and Thrombosis, Unilabs Slovakia, Kosice,Slovakia; 2University Hospital of L.Pasteur, Kosice, Slovakia Background: DOACs are helpful in preventing and treating VTE. Even so, in clinical practice, remedy failure (recurrent VTE, postthrombotic syndrome) and unexpected alterations in coagulation tests happen. Aims: We present uncommon complications of DOAC treatment (rivaroxaban, dabigatran, apixaban) in adequately anticoagulated patients: recurrent VTE, post-thrombotic syndrome, thrombocytopenia, coagulation element deficiency, FVIII inhibitor. Solutions: 18 patients with proximal reduced limb thrombosis, pulmonary embolism, adequately anticoagulated; lab
